<h4>Objectives</h4>There are no standardized criteria about stepping down from combination therapy (immunomodulator and tumor necrosis factor (TNF)-alpha-inhibitors) in children with inflammatory bowel disease (IBD) to reduce risk for side effects. The gene discussed is TNF; the disease is inflammatory bowel disease.